Modern possibilities for complex therapy of infectious and inflammatory diseases of the cervix and vagina in the practice of an obstetrician-gynecologist

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

The effective treatment and prevention of recurrence of infectious and inflammatory diseases of the cervix and vagina require careful diagnosis and therapy.

Objective: To evaluate the efficacy of peptide-protein complex containing natural peptides and cytokines in the therapy of cervicitis and vaginitis with mixed etiology.

Materials and methods: This study presents a comparative analysis of the results of therapy for 80 patients diagnosed with cervicitis, which was associated with bacterial vaginosis (BV), vulvovaginal candidiasis (VVC), and human papillomavirus (HPV). The patients were divided into two groups: group 1 (n=40) received standard therapy in combination with a complex of natural peptides and cytokines (the Superlymph drug, suppositories administered rectally at a dose of 25 IU twice a day for 20 days); group 2 (n=40) received standard therapy without peptide-protein complex. The effectiveness of the treatment was evaluated on the basis of the patient’s complaints, clinical picture of the disease and the results of laboratory tests at one and three months after the end of therapy.

Results: After one month of treatment, 2/40 (5%) patients in group 1 continued to experience pathologic discharge from the genital tract. In group 2, clinical manifestations of the disease in the form of moderate genital discharge, itching and vaginal discomfort were noted in 6/40 (15%) women. HPV DNA testing showed the absence of HPV in 57.5% of patients in group 1 and in 27.5% of women in group 2. The median viral load was calculated again: it was 3.9 lg (3.3; 4.5) in group 1 and 4.4 lg (3.8; 4.9) in group 2. After three months, no recurrence of the disease was detected in group 1; however, 4/40 (10%) women in group 2 were diagnosed with recurrent episodes of cervicitis which was associated with BV and VVC in two cases, BV in one case, and aerobic vaginitis in one case.

Conclusion: Due to the frequent recurrence of the disease resulting from inadequate efficacy of therapy, it is extremely important to prescribe treatment that targets each etiologic agent of the disease. The use of the medication based on natural peptides and cytokines showed high efficacy in the complex treatment of cervicitis and vaginitis.

About the authors

Guldana R. Bayramova

Academician V.I. Kulakov National Medical Research Centre for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Author for correspondence.
Email: bayramova@mail.ru
ORCID iD: 0000-0003-4826-661X

Dr. Med. Sci., Merited Doctor of the Russian Federation, Professor at the Department of Obstetrics and Gynecology of the Department of Professional Education

Russian Federation, Moscow

Alexander O. Andreev

Academician V.I. Kulakov National Medical Research Centre for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: sasha.grash2010@yandex.ru
ORCID iD: 0000-0002-9835-440X

obstetrician gynecologist at the Research and Outpatient Department

Russian Federation, Moscow

Izabel B. Kecherukova

N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia

Email: kecherukovaib@gmail.com
ORCID iD: 0000-0002-6650-6456

6th-Year Student

Russian Federation, Moscow

References

  1. Shroff S. Infectious vaginitis, cervicitis, and pelvic inflammatory disease. Med. Clin. North Am. 2023; 107(2): 299-315. https:/dx.doi.org/10.1016/ j.mcna.2022.10.009.
  2. Байрамова Г.Р., Прилепская В.Н., Смольникова В.Ю., Юренева С.В. и др. ВПЧ-ассоциированный цервицит: диагностика, лечение и профилактика. Учебное пособие. М: «ИД Третьяковъ»; 2022. 90с. [Bayramova G.R., Prilepskaya V.N., Smolnikova V.Yu., Yureneva S.V. et al. HPV-associated cervicitis: diagnosis, treatment and prevention. Study guide. M: Tretyakov Publishing House LLC; 2022. 90 p. (in Russian)].
  3. Iqbal U., Wills C. Cervicitis. 2023 Sep 4. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–.
  4. Satterwhite C.L., Torrone E., Meites E., Dunne E.F., Mahajan R., Ocfemia M.C. et al. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008. Sex. Transm. Dis. 2013; 40(3): 187-93. https:/ dx.doi.org/10.1097/OLQ.0b013e318286bb53.
  5. Савельева И.В., Полянская И.Б., Галянская Е.Г., Шевлягина Л.С., Широкова О.В., Гимп М.В., Флоров А.Ю., Никерина Н.И. К вопросу об улучшении исходов лечения хронического цервицита. Медицинский Совет. 2018; 13: 104-8. [Savelyeva I.V., Polyanskaya I.B., Galyanskaya E.G., Shevlyagina L.S., Shirokova O.V., Gimp M.V., Florov A.Y., Nikerina N.I. Improving outcomes in the treatment of chronic cervicitis. Medical Council 2018; (13): 104-8. (in Russian)]. https:/dx.doi.org/10.21518/ 2079-701X-2018-13-104-108.
  6. Bittleston H., Hocking J.S., Goller J.L., Coombe J., Bateson D., Sweeney S. et al. Is there a place for a molecular diagnostic test for pelvic inflammatory disease in primary care? An exploratory qualitative study. PLoS One. 2022; 17(9): e0274666. https:/dx.doi.org/10.1371/journal.pone.0274666.
  7. Salmanov A.G., Artyomenko V., Koctjuk I.M., Mashyr N.V., Berestooy O.A., Beraia D.Y. Cervicitis as a cause of preterm birth in women. Wiad. Lek. 2022; 75(11 pt 2): 2715-21. https:/dx.doi.org/10.36740/WLek202211201.
  8. Liu H., Liang H., Li D., Wang M., Li Y. Association of cervical dysbacteriosis, HPV oncogene expression, and cervical lesion progression. Microbiol. Spectr. 2022; 10(5): e0015122. https:/dx.doi.org/10.1128/spectrum.00151-22.
  9. Chen X., Guo H. Comparison of chlorquinaldol-promestriene vaginal tablets and opin suppositories effect on inflammatory factors and immune function in chronic HPV cervicitis. J. Coll. Physicians Surg. Pak. 2019; 29(2): 115-8. https://dx.doi.org/10.29271/jcpsp.2019.02.115.
  10. Амирханян А.С., Байрамова Г.Р., Киселев В.И., Прилепская В.Н., Полозников А.А., Бурменская О.В., Бабкина И.О., Асатурова А.В. Хронический цервицт, ассоциированный с вирусом папилломы человека и маркеры воспаления у женщин репродуктивного возраста. Акушерство и гинекология. 2019; 4: 49-57. [Amirkhanyan A.S., Bayramova G.R., Kiselev V.I., Prilepskaya V.N., Poloznikov A.A., Burmenskaya O.V., Babkina I.O., Asaturova A.V. Chronic cervicitis associated with human papillomavirus and markers of inflammation in women of reproductive age. Obstetrics and Gynecology. 2019; (4): 49-57. (in Russian)]. https:// dx.doi.org/10.18565/aig.2019.4.49-57.
  11. Nelson C.W., Mirabello L. Human papillomavirus genomics: Understanding carcinogenicity. Tumour Virus Res. 2023; 15: 200258. https:// dx.doi.org/10.1016/j.tvr.2023.200258.
  12. Погодина В.А., Бабенко А.И., Бабенко Е.А., Хаятова З.Б. Аналитическая оценка здоровья у лиц молодого возраста (18-29 лет) в Новосибирске. Казанский медицинский журнал. 2018; 99(1): 116-21. [Pogodina V.A., Babenko A.I., Babenko E.A., Khayatova Z.B. Analytical health evaluation of young age persons (18-29 years) in the city of Novosibirsk. Kazan Medical Journal. 2018; 99(1): 116-21. (in Russian)]. https://dx.doi.org/10.17816/KMJ2018-116.
  13. Савельева И.В., Полянская И.Б. Возможности комбинированной терапии у больных бактериальным вагинозом в сочетании с кандидозным вульвовагинитом. Российский вестник акушера-гинеколога. 2016; 16(3): 69-72. [Savel'eva I.V., Polyanskaya I.B. Possibilities for combined therapy in patients with bacterial vaginosis concurrent with vulvovaginal candidiasis. Russian Bulletin of Obstetrician-Gynecologist. 2016; 16(3): 69-72. (in Russian)]. https://dx.doi.org/10.17116/rosakush201616369-72.
  14. Кореева Н.В., Доброхотова Ю.Э. Применение локальной цитокинотерапии в акушерско-гинекологической практике. Российский вестник акушера-гинеколога. 2013; 13(5): 99-104. [Koreeva N.V., Dobrokhotova Iu.É. Use of local cytokine therapy in obstetric/gynecologic practice. Russian Bulletin of Obstetrician-Gynecologist. 2013; 13(5): 99-104. (in Russian)].
  15. Hillier S.L., Bernstein K.T., Aral S. A review of the challenges and complexities in the diagnosis, etiology, epidemiology, and pathogenesis of pelvic inflammatory disease. J. Infect. Dis. 2021; 224(12 Suppl. 2): S23-S28. https:// dx.doi.org/10.1093/infdis/jiab116.
  16. Хурасева А.Б., Гайдарова А.Х., Манжосова М.И., Роговская С.И. Оптимизация лечения цервицитов в раннем репродуктивном возрасте с помощью локальной цитокинотерапии. Российский вестник акушера-гинеколога. 2016; (3): 48-51. [Khuraseva A.B., Gaidarova A.Kh., Manzhosova M.I., Rogovskaia S.I. Optimization of local cytokine therapy for cervititis at an early reproductive age. Russian Bulletin of Obstetrician-Gynecologist. 2016; (3): 48-51. (in Russian)]. https:/dx.doi.org/10.17116/rosakush201616348-51.
  17. Селина Н.Н., Роговская С.И., Созаева Л.Г., Тумгоева Л.Б., Фадеев И.Е. Индукторы мукозального иммунитета в комбинации с радиоволновой эксцизией шейки матки при лечении пациенток с тяжелыми интраэпителиальными поражениями шейки матки. Клинические и иммунологические аспекты. Российский вестник акушера-гинеколога. 2018; 18(2): 107-13. [Selina N.N., Rogovskaia S.I., Sozaeva L.G., Tumgoeva L.B., Fadeev I.E. Inductors of mucosal immunity in combination with radiowave cervical excision in the treatment of patients with high-grade cervical intraepithelial lesions. Clinical and immunological aspects. Russian Bulletin of Obstetrician-Gynecologist. 2018; 18(2): 107-13. (in Russian)]. https:// dx.doi.org/10.17116/rosakush2018182107-113.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Clinical efficacy before and after therapy in the studied groups of patients

Download (65KB)
Indexing metadata
3. Fig. 2. HPV viral load before and after treatment depending on the prescribed therapy

Download (55KB)
Indexing metadata

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies